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Supplementary Figure 1 The effect of divalent metals on primase activity and 
nucleotide binding. a) Fluorescence-based RNA primer synthesis assay on a ssDNA 
template (5¢-GTTGTCCATTATGTCCTACCTCGTGCTCCT) in the presence of 5 mM 
Mg2+ ions and equimolar concentrations of ribonucleotides (20 µM each rNTP) and 
the indicated nucleotide analogue (20 µM). Curves are colored as follows: ATP (red), 
vidarabine-TP (light blue), fludarabine-TP (orange). b) Fluorescence polarization was 
used to determine the binding affinity of a Pri1 mutant (WT – black triangles, D109A 
point mutant – open triangles) for 6FAM-ATP in the presence of 1 mM Mn2+ ions (left 
panel). The D109A mutation removes one of the metal-coordinating side-chains and 
thus prevents nucleotide binding to the Pri1 elongation site. The fact that this point 
mutant no longer binds 6FAM-ATP indicates that the binding is specific to the 
elongation site and the 6FAM label does not mediate non-specific binding to Pri1. Both 
WT Pri1 and the D109A point mutant eluted at the same volume from a Superdex S75 
size exclusion column (GE Healthcare), indicating that the D109A mutant is likely 
properly folded (right panel). Coomassie-stained SDS-PAGE gel of final, purified 
proteins is shown as inset panel. c) Fluorescence polarization was used to determine 
the binding affinity of WT Pri1 for 6FAM-ATP in the presence of 1 mM Mn2+ ions (Kd 
= 0.41 µM) (left panel), and 1 mM Mg2+ ions (right panel). Each data point represents 
the mean ± s.d. (n=3).  
 
 
 
 
 
 
  
Supplementary Figure 2 Nucleotide binding to the elongation site of Pri1. Fo-Fc omit 
maps (calculated by omitting the nucleotide) are shown for the (a) ATP, (b) dATP, (c) 
2F-ATP, (d) vidarabine-TP and (e) fludarabine-TP structures (Fo-Fc maps are 
contoured at 3.0 s). f) Superposition of the crystal structures of Pri1 bound to ATP 
(beige), dATP (purple), 2F-ATP (pink), vidarabine-TP (green) and fludarabine-TP 
(blue). Key nucleotide- and metal-binding side-chains are shown. Mn2+ ions are shown 
as purple spheres. All images were generated using Chimera.53 
 
 
 
 
 
 
 
 Supplementary figure 3 Cordycepin-TP is poorly incorporated into an RNA primer 
and only inhibits primase activity at relatively high concentrations. a) Denaturing gel 
showing incorporation of cordycepin or fludarabine into an existing RNA primer. The 
template comprised a 38-mer DNA (5¢-T20CCAGAGAGCGCCCAAACG) annealed to 
an 18-mer RNA (5¢-CGUUUGGGCGCUCUCUGG). Reactions contained 0.5 µM 
template, 0.5 µM primase, 10 mM Mg(OAc)2 and 500 µM of either ATP, fludarabine-
TP or cordycepin-TP. Reactions were incubated at 37 °C for 30 minutes, and the 
products were analyzed by denaturing polyacrylamide gel electrophoresis. b) 
Denaturing gel showing the effect of cordycepin-TP on RNA primer synthesis. 
Reactions contained 0.5 µM polydT40 ssDNA template, 0.5 µM primase, 500 µM ATP, 
10mM Mg(OAc)2 and the indicated concentration of cordycepin-TP. Reactions were 
incubated and analyzed as in (a). All gels were post-stained with Sybr Gold. M = 
marker. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Supplementary figure 4 The effect of cytarabine-TP, clofarabine-TP and 
gemcitabine-TP on RNA primer synthesis. a) FP-based competition binding 
experiment in which 6FAM-ATP (30 nM) in the presence of excess Pri1 (1.5 µM) was 
challenged with increasing concentrations of the indicated nucleotide (ATP) or 
nucleotide analogue (cyt-TP: cytarabine triphosphate, gem-TP: gemcitabine 
triphosphate, clo-TP: clofarabine triphosphate). Each data point represents the mean 
± s.d. (n=3, except cyt-TP for which n=6). b) Denaturing gel showing the incorporation 
of nucleotide analogues into an existing RNA primer. The template comprised a 38-
mer DNA template (5¢-T16TTTTCCAGAGAGCGCCCAAACG) annealed to an 18-mer 
RNA (5¢-CGUUUGGGCGCUCUCUGG). For the cytosine analogues (cytarabine-TP 
and gemcitabine-TP) the DNA template was instead 5¢-
T16GGGGCCAGAGAGCGCCCAAACG. Reactions contained 0.5 µM annealed DNA-
RNA template, 0.5 µM primase, 10 mM Mg(OAc)2, and 500 µM of either ATP, dATP, 
vid-TP, clo-TP, flu-TP, cyt-TP or gem-TP. Reactions were allowed to proceed for 5 or 
30 minutes at 37 °C before quenching and subsequent separation of the products on 
an 18% polyacrylamide-urea gel. Gels were post-stained with Sybr Gold. M = marker. 
 
 
 
 
 
 
 
 
 
 
 
  
Supplementary figure 5 A C-terminal truncation does not affect the priming activity 
of human primase. Denaturing gel showing the time-course of RNA primer synthesis 
on a 30-mer ssDNA template by Pri1(1-420)-Pri2(1-509) and Pri1(1-420)-Pri2(1-462). 
Primer products were visualized by post-staining the urea-polyacrylamide gel with 
Sybr Gold. 
 
 
